PUBLICATIONS
|
|
LATIGLUTENASE: |
|
Murray JA, Syage, JA, Wu T-T, Dickason MA, et al. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge, Gastroenterology 2022; 163:1510-1521. https://doi.org/10.1053/j.gastro.2022.07.071 Syage JA et al., Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet. GastroHep 2019;1:293-301. https://doi.org/10.1002/ygh2.371 Syage JA, Murray JA, Green PHR, Khosla, C. Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet. Dig Dis & Sci 2017;62:2428-2432. https://doi.org/10.1007/s10620-017-4687-7 Moron B, Verma AK, Khosla C et al. CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. Am J Gastroenterol 2013;108:1-8. https://doi.org/10.1038/ajg.2013.151
Leffler D, Kupfer SS, Lebwohl B, Bugin K, Griebel D, et al., Development of Celiac Disease Therapeutics: Report of the Third Gastroenterology Regulatory Endpoints and Advancement of Therapeutics Workshop. Gastroenterology 2016;151:407–411. https://doi.org/10.1053/j.gastro.2016.07.025 Green PHR, Lebwohl B, Greywoode R. Celiac disease. J Allergy Clin Immunol 2015;135:1099-1106. https://doi.org/10.1016/j.jaci.2015.01.044 Kelly CP, Bai, JC, Liu E, Leffler DA. Celiac disease: clinical spectrum and management. Gastroenterol 2015;148:1175-1186. https://doi.org/10.1053/j.gastro.2015.01.044 Rubio-Tapia A, Murray JA. Celiac disease. Curr Opin Gastroenterol 2010;26:116–22. https://doi.org/10.1097/mog.0b013e3283365263 Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912–33. https://doi.org/10.1053/j.gastro.2009.09.008 |
|
|
ADRULIPASE: |
|
“Results from an Open-Label, Phase 2 STUDY with Escalating Doses of Adrulipase Alfa on top of a Stable Dose of Porcine Pancreatic Enzymes (PPE) in CF Patients Not Fully Compensated with PPE as Sole Therapy”. Konstan M, Karadag B, Srinivasan D, Pennington J. 2023 Digestive Disease Week (DDW) Presentation. "Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase." Desai H, Conlon D, Brown A, Draganov A, Tagliaferri F, Srinivasan D, Brieger M, Stover, T. AAPS 2022 PHarmSCi 360 Conference Poster. “A Phase 2, Open-Label, Multicenter, 2×2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis”. Konstan M, McBennett K, Boas S, Mazurek H, Gangal M, Srinivasan D, Pennington J. 2020 Digestive Disease Week (DDW) Presentation. “Impact of a spray dried recombinant lipase, MS1819, For the treatment of exocrine pancreatic insufficiency in patients with chronic pancreatitis. Results of a multicenter, Phase II, open-label, non-randomized study”. Nguyen, N, Lebreton, L, Smith G, Jais P, Schue M, Spoor, T. 2019 Digestive Disease Week (DDW) Presentation. “Yarrowia lipolytica Lipase 2 is Stable and Highly Active in Test Meals and Increases Fat Absorption in an Animal Model of Pancreatic Exocrine Insuffiency.” Aloulou A, Schué M, Puccinelli D, Milano S, Delchambre C, Leblond Y, Laugier R, Carrière F. Gastroenterology. December 2015. 149(7):1910-1919 |
|
|
NICLOSAMIDE: |
|
Marafini, I, De Crisofaro, E., Salavatori, S, Calabrese, E, Lolli, E, Monteleone, I, Franchi, L, Ciccopcioppo, R, Glick, G, Opipari, A, Monteleone, G. Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study. Inflamm Bowel Dis. 2023 July 21. Read more. “Niclosamide Enemas, A Safe And Effective Treatment In Mild To Moderate Ulcerative Proctitis/Proctosigmoiditis: Results From An Open Label Study”. Marafini I, Monteleone G, Salvatori S, Ciccocioppo R , Opipari A, Pennington J , Piccirillo M.. 2022 Digestive Disease Week (DDW) Presentation. Shin, B., Benavides, G. A., Geng, J., Koralov, S. B., Hu, H., Darley-Usmar, V. M., & Harrington, L. E. (2020). Mitochondrial oxidative phosphorylation regulates the fate decision between pathogenic Th17 and regulatory T cells. Cell Reports, 30(6), 1898-1909. doi:10.1016/j.celrep.2020.01.022. Read more. Fuseini, H., Cephus, J., Wu, P., Davis, J. B., Contreras, D. C., Gandhi, V. D., Rathmell, J. C., & Newcomb, D. C. (2019). ERα signaling increased IL-17A production in Th17 cells by upregulating IL-23R expression, mitochondrial respiration, and proliferation. Frontiers in Immunology, 10. doi:10.3389/fimmu.2019.02740. Read more. Kaufmann, U., Kahlfuss, S., Yang, J., Ivanova, E., Koralov, S. B., & Feske, S. (2019). Calcium Signaling Controls Pathogenic Th17 Cell-Mediated Inflammation by Regulating Mitochondrial Function. Cell Metabolism, 29(5), 1104-1118. doi:10.1016/j.cmet.2019.01.019. Read more. Franchi, L., Monteleone, I., Hao, L., Spahr, M. A., Zhao, W., Liu, X., Demock, K., Kulkarni, A., Lesch, C. A., Sanchez, B., Carter, L., Marafini, I., Hu, X., Mashadova, O., Yuan, M., Asara, J. M., Singh, H., Lyssiotis, C. A., Monteleone, G., Opipari, A. W., & Glick, G. D. (2017). Inhibiting oxidative phosphorylation in vivo restrains Th17 effector responses and ameliorates murine colitis. The Journal of Immunology, 204(2). doi:10.4049/jimmunol.1600810. Read more. Tao, H., Zhang, Y., Zeng, X., Shulman, G. I., & Jin, S. (2014). Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice. Nature Medicine, 20(11), 1263-1269. doi:10.1038/nm.3699. Read more |
